Mounjaro Is Now Approved to Lower the Risk of Heart Events

Mounjaro Is Now Approved to Lower the Risk of Heart Events

Regulators expanded approval of Mounjaro to include lowering heart-related risks in people with Type 2 diabetes.

• Mounjaro is made by Eli Lilly.
• The new approval covers people with Type 2 diabetes.
• The indication relates to lowering the risk of heart events.
• This is an expansion beyond the drug's original approved use.

TIME

The often unexpected benefits of taking a GLP-1

GLP-1 drugs may offer effects beyond weight loss, though some claims outpace current scientific evidence.

• Article reviews what scientists currently know about GLP-1 medications.
• Piece distinguishes established evidence from claims not yet fully supported.
• Focus is on effects beyond the primary uses these drugs were developed for.
• Source notes some public hype may be ahead of the research.

USA TODAY